TSHR Inhibitors
1 drugsAbout TSHR
TSHR (Thyrotropin Receptor) is a GPCR primarily regulating thyroid hormone synthesis and secretion. Its activation modulates cellular signaling pathways, extending its relevance beyond thyroid disorders. TSHR is being explored in oncology.
TSHR's therapeutic potential lies in modulating cellular signaling pathways. Currently, there is no genetic evidence available linking TSHR to specific diseases. Drugs targeting TSHR could offer novel therapeutic strategies.
TSHR is targeted by one FDA-approved drug, THYROGEN (Sanofi), a biologic used in oncology. THYROGEN was first approved in 1998 and remains the only approved drug.
Top TSHR Drugs
Sanofi is the only company with an approved TSHR-targeting drug.
Low competition suggests a high barrier to entry or untapped market potential for new entrants.
TSHR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TSHR, using enzyme modality.
The lack of modality diversity suggests an opportunity for small molecule or antibody-based TSHR therapeutics.
TSHR Clinical Trials 3 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TSHR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TSHR Drug Approval Timeline (1998 - 1998)
THYROGEN was approved in 1998 and no new drugs have been approved since.
The stagnant approval timeline indicates a saturated market or challenges in developing new TSHR-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TSHR. A trial counts if an approved drug acting on TSHR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.